EQ · Equillium, Inc.
AI read · Good for EQ
The AI's read
Moving EQ504 into a study in people gives Equillium a chance to test its approach. Results are not expected until Q2 2027, and the planned patient study depends on supportive findings. The company also expects its cash to last into 2029. The $20 million equity sale adds funding, but may leave existing owners with a smaller share. Together, the trial start and cash runway make the update favorable despite those concerns.